As a first author
- Breaking the therapeutic ceiling in drug development in ulcerative colitis.
The Lancet Gastroenterology and Hepatology PMID: 34019798
- Utility of the serum-based Endoscopic Healing Index in monitoring therapeutic response in ulcerative colitis.
The American Journal of Gastroenterology PMID: 37753938
- Calibration, clinical utility and specificity of clinical decision support tools in inflammatory bowel disease.
Clinical Gastroenterology and Hepatology PMID: 39461468 Analysis notebook
- Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.
Journal of Crohn’s and Colitis PMID: 3533353
- Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study.
Inflammatory Bowel Diseases PMID: 38215029 Analysis notebook
- Best practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Therapeutic Drug Monitoring PMID: 38648666
- Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Current Opinion in Pharmacology PMID: 33039940
- Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.
Current Research in Pharmacology and Drug Discovery PMID: 35146421
- Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?
Clinical Gastroenterology and Hepatology PMID: 35850410
- Immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
Alimentary Pharmacology & Therapeutics PMID: 35315101
- The serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.
Journal of Crohn’s and Colitis PMID: 37178692
- Beyond discrimination: a call for comprehensive assessment of clinical prediction models in inflammatory bowel disease.
Inflammatory Bowel Diseases PMID: 38460148
- Ustekinumab and vedolizumab exposure is unaffected by pharmacogenetic determinants of anti-TNFs pharmacokinetics.
Inflammatory Bowel Diseases PMID: 38581670
As a co-author
- Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all.
Journal of Crohn’s and Colitis PMID: 35150242
- Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Alimentary Pharmacology & Therapeutics PMID: 35484689
- Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease.
Therapeutic Advances in Gastroenterology PMID: 37655059
- Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center.
European Journal of Gastroenterology and Hepatology PMID: 36062494
- Translating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD.
Inflammatory Bowel Diseases PMID: 34751766
- The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.
British Journal of Clinical Pharmacology PMID: 33604964